Form 4: Dynavax Technologies CFO Kelly MacDonald Reports Stock Transactions

Kelly MacDonald, CFO of Dynavax Technologies, reports the vesting of restricted stock units, stock option grants, and related tax withholding.

Summary

• On February 13, 2025, Kelly MacDonald, the SVP and CFO of Dynavax Technologies, engaged in several transactions involving the company's stock.
• MacDonald acquired 16,000 shares of common stock through the vesting of restricted stock units (RSUs).
• 5,318 shares were withheld by Dynavax to satisfy tax obligations related to the vesting of these RSUs at a price of $12.69 per share.
• MacDonald was also granted an option to purchase 70,000 shares of common stock, vesting over three years.
• Additionally, MacDonald acquired 42,424 restricted stock units that vest over three years.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It simply reports transactions by a company insider, which is a routine part of corporate governance. There are no explicit positive or negative implications.

Positives

• The vesting of RSUs and granting of stock options to the CFO could be seen as a positive sign, aligning management's interests with those of shareholders.
• The vesting schedule of the stock options (over three years) encourages long-term commitment from the CFO.

Negatives

• The withholding of shares for tax obligations reduces the immediate net gain for the reporting person.

Risks

• Future stock price fluctuations could impact the value of the stock options and RSUs.
• Changes in company performance could affect the vesting of performance-based RSUs.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a multi-year commitment from the CFO.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The vesting of RSUs and granting of stock options are common compensation practices.

Comparison to Industry Standards

• Stock option grants and RSU vesting are standard compensation practices for executives in publicly traded companies, particularly in the biotechnology sector.
• Companies like Moderna (MRNA) and BioNTech (BNTX) also utilize stock options and RSUs as part of their executive compensation packages to align management incentives with shareholder value.
• The vesting schedules (three years) are typical for such grants, encouraging long-term commitment.

Stakeholder Impact

• The transactions could have a minor impact on shareholders by potentially diluting the stock if the options are exercised.
• Employees may view the executive compensation package as a sign of company confidence.

Key Dates

Keywords

Dynavax Technologies, DVAX, Kelly MacDonald, CFO, Form 4, Stock Options, Restricted Stock Units, RSU, Vesting, Tax Withholding, Beneficial Ownership